PLATINUM MUSCLE AND BACK PAIN RELIEF TABLET
Država: Kanada
Jezik: angleščina
Source: Health Canada
Lastnosti izdelka
(SPC)
24-01-2011
Nekateri dokumenti za ta izdelek trenutno niso na voljo, pošljete lahko zahtevo v našo stranko in obvestili vas bomo takoj, ko jih bomo lahko pridobili.
Pošlji zahtevo.
Pošlji zahtevo.
Aktivna sestavina:
METHOCARBAMOL; IBUPROFEN
Dostopno od:
VITA HEALTH PRODUCTS INC
Koda artikla:
M03BA53
INN (mednarodno ime):
METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS
Odmerek:
500MG; 200MG
Farmacevtska oblika:
TABLET
Sestava:
METHOCARBAMOL 500MG; IBUPROFEN 200MG
Pot uporabe:
ORAL
Enote v paketu:
18/27/40/50/80
Tip zastaranja:
OTC
Terapevtsko območje:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Povzetek izdelek:
Active ingredient group (AIG) number: 0248961001; AHFS:
Status dovoljenje:
APPROVED
Datum dovoljenje:
2011-01-20
Lastnosti izdelka
PRODUCT MONOGRAPH
PLATINUM MUSCLE AND BACK PAIN RELIEF
500 MG METHOCARBAMOL AND 200 MG IBUPROFEN CAPLETS
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
VITA HEALTH PRODUCTS INC.
DATE OF PREPARATION:
150 BEGHIN AVENUE,
January 17, 2011
WINNIPEG, MB
CANADA, R2J 3W2
CONTROL NO.: 128349
2
TABLE OF CONTENTS
Page
CLINICAL
PHARMACOLOGY.............................................................................................3
INDICATIONS:
...............................................................................................................6
CONTRAINDICATIONS
.....................................................................................................6
WARNINGS:
.................................................................................................................7
PRECAUTIONS
.............................................................................................................10
DRUG INTERACTIONS
...................................................................................................12
ADVERSE
REACTIONS..................................................................................................13
SYMPTOMS AND TREATMENT OF OVERDOSE
...............................................................15
DOSAGE AND
ADMINISTRATION...................................................................................16
PHARMACEUTICAL
INFORMATION.................................................................................16
COMPOSITION
............................................................................................................19
AVAILABILITY OF DOSAGE
FORMS................................................................................19
INFORMATION FOR THE CONSUMER
.............................................................................20
PHARMACOLOGY
..............................................................................................22
CLINICAL TRIALS
..........................................................................................
Preberite celoten dokument
